कंपनी का अवलोकन
XOMA Royalty Corporation operates as a specialized biotech royalty aggregator, securing economic rights to future milestone and royalty payments derived from both commercial products and pre-commercial therapeutic candidates across the United States, Switzerland, Asia Pacific, and Australia. This entity functions within the broader Healthcare sector, specifically targeting the Biotechnology industry, where it monetizes intellectual property portfolios without necessarily engaging in direct drug development. The company maintains a lean operational structure with a workforce of 14 employees, which supports its asset-light business model focused on licensing agreements. Its total market capitalization is listed as N/A, and its trailing twelve-month revenue stands at $52.15M, indicating a mid-cap profile typical for royalty-focused firms. The revenue figure of $52.15M suggests a significant income stream relative to its minimal employee base, while the N/A market cap status implies that valuation metrics are derived primarily through enterprise value calculations rather than traditional equity market cap comparisons, reflecting the unique nature of royalty-only business models.
वित्तीय स्वास्थ्य
The company reported a revenue of $52.15M for the trailing twelve months, generating a net income of $18.52M and an EBITDA of $14.36M. The substantial gap between revenue and net income, where profit margin reaches 60.8%, reveals an exceptionally efficient cost structure with low variable costs relative to sales volume. However, the free cash flow stands at -$14,235,375, which indicates that the company is currently burning cash, potentially due to strategic investments or timing differences in royalty collections, thereby limiting immediate financial flexibility for large-scale capital expenditures. Despite the negative cash flow, the balance sheet holds $83.29M in cash against $131.56M in debt, resulting in a debt-to-equity ratio of 126.54, which signifies a highly leveraged position rather than a conservative one. The current ratio of 3.37 demonstrates strong short-term liquidity, suggesting the firm can easily meet its immediate obligations despite the overall leverage. Return on Equity is reported at 34.1%, highlighting efficient generation of returns from shareholder capital, while Return on Assets sits at 2.9%, indicating that asset utilization is moderate given the company's heavy reliance on intangible royalty assets rather than physical infrastructure.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is 26.45, while the forward P/E is N/A, implying that analysts do not have a projected earnings trajectory sufficient to calculate a future price-to-earnings multiple at this time. The price-to-book ratio is 3.74, indicating that the market values the company at a significant premium over its tangible book value, likely due to the high profitability and intangible asset quality of the royalty portfolio. Alternative valuation metrics such as the EV/EBITDA of 26.72 and the N/A price-to-sales ratio provide additional context, suggesting the market is willing to pay a high multiple for earnings before interest, taxes, depreciation, and amortization. The stock's 52-week price range spans from a low of $24.96 to a high of $30.00, with the current trading price positioned relative to this historical volatility. The beta of 0.68 indicates that the stock exhibits lower price volatility compared to the broader market, moving less sharply during periods of market turbulence. These valuation figures collectively paint a picture of a high-multiple asset that trades with less systemic risk but carries significant leverage risk.
Growth & Income
Revenue growth over the past year is 57.9%, whereas earnings growth is N/A, suggesting that while top-line sales are expanding rapidly, the earnings base may be constrained by the aforementioned negative free cash flow or specific accounting treatments of the royalty streams. As a dividend payer, the company offers a yield of 8.1%, yet the payout ratio is N/A, which complicates the assessment of sustainability given the negative free cash flow and the lack of a defined earnings base for the dividend. The absence of a calculated payout ratio combined with negative cash flow suggests that the dividend may be funded from cash reserves rather than current operating earnings, posing a potential risk to long-term income stability. Overall, the growth and income profile presents a dichotomy of high revenue expansion and an attractive but potentially fragile dividend yield supported by a leveraged balance sheet and negative cash flow generation.